

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

### **VOLUNTARY ANNOUNCEMENT**

#### **SIHUAN PHARMACEUTICAL OBTAINED CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FROM NMPA FOR EXCLUSIVELY DISTRIBUTED DUAL WAVE RF TREATMENT DEVICE SYLFIRM X**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Sylfirm X (the “**Product**”), a dual wave radio frequency (“**RF**”) treatment device, which is exclusively distributed by the Group and produced by VIOL Co., Ltd. of South Korea (“**VIOL Korea**”), obtained Class III medical device registration certificate from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (the “**China**”) on 19 March 2024.

Sylfirm X is the world’s first FDA and NMPA registered dual wave RF treatment device. It can effectively reduce skin wrinkles and treat atrophic acne scars by emitting high-frequency electrical currents to induce coagulation of skin tissues.

The Product adopts PW (pulsed wave) and CW (continuous wave) dual-wave RF pulse type, through eight dual-wave treatment modes namely PW1, PW2, PW3, PW4/CW1, CW2, CW3, CW4, and adopts the bipolar non-insulated microneedle electrodes, which can cover the entire skin dermal layer for treatment, with a uniform energy output and a significant therapeutic effect. It targets 0.3mm-4mm subcutaneous precise treatment, and the clinical effect shows that there is no serious adverse reaction related to the treatment and is with short recovery period after surgery. Through 300µm 0.3s precise treatment, it is comfortable and painless without bleeding.

There are 25+ clinical publications proving the safety and efficacy of Sylfirm X. Its patented “NA effect” maximises the thermal effect on the target tissue with almost no epidermal damage. <0.3s tissue response starts at the tip of the microneedle electrode, thus achieving an effective and safe treatment, making the Product an advanced treatment and care for people with all skin types and problematic skin.

Meiyan Space announced on 10 January 2022 that it has reached an exclusive distribution agreement with VIOL Korea for Sylfirm X, and obtained the exclusive distribution right for the Product in Chinese Mainland, Hong Kong and Macau. The term of the agreement is ten years from the date on which the Product is granted local registration approval (including, but not limited to, the approval from the NMPA), and it is the first time that the Product has been marketed in these territories.

Founded in 2009, VIOL Korea is dedicated to the research and production of medical devices in combination with biotechnology and electronics. It has launched three brands, namely Sylfirm X, Omedia and Scarlet S since 2015. With its outstanding technical strength, VIOL Korea’s products have been distributed in 45 countries and widely recognized worldwide.

### **About Meiyan Space**

Meiyan Space is the medical aesthetics subsidiary of Sihuan Pharmaceutical. Based on the high-growth and low-penetration medical aesthetics market which is experiencing explosive growth in China, Meiyan Space has successfully established a “one-stop” new medical aesthetics platform in China and is dedicated to building a leading company featuring full medical aesthetics product matrix in China by leveraging the rigour and innovation of pharmaceutical companies through globalized layout and localized production, comprehensive and professional medical aesthetics product matrix, strong product R&D and registration capabilities as well as diversified marketing channel ability.

Sihuan Pharmaceutical has a forward-looking layout in the medical aesthetics field. Since the Group entered into an exclusive distribution agreement in China with Hugel, Inc., a leading biomedical company in South Korea, in relation to botulinum toxin Letybo® and hyaluronic acid Persinca™ in 2014, with years of development, Meiyan Space has built a complete product matrix across medical aesthetics value chain with “self-development+BD” dual engine drivers. Taking the coverage of the whole life cycle needs of beauty enthusiasts as the starting point, its product layout covers a variety of high-quality medical aesthetics products, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others. Meiyan Space is equipped with strong in-house R&D and technology transformation capabilities, and its current R&D pipelines has more than ten self-developed class III medical aesthetics products and tens of class II medical aesthetics products. Besides, Meiyan Space has established the Meiyen Laboratory in Los Angeles, the United States, to conduct innovative technology introduction, independent research and development of new generation medical aesthetics products and biomaterial, and the technology transformation and manufacture in China. Leveraging the global resources of Sihuan Pharmaceutical, the parent company, Meiyan Space has strong product registration, manufacture and sales capabilities

and is able to accelerate the launch of new products. At present, Meiyang Space has completed the construction of two domestic manufacture bases with a gross floor area of 16,000 square meters. It has currently planned for 7 production lines equipped with optimized quality management system and is able to implement effective risk management in the whole life cycle of products. Most members in the sales team of Meiyang Space come from multinational medical aesthetics and pharmaceutical enterprises with rich sales experience for medical aesthetics products. They work closely with tens of agents with the sales network covering more than 350 cities and 4,700 medical aesthetics institutions nationwide.

### **About Sihuan Pharmaceutical**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 25 March 2024

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*